Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Wales’ New Treatments Fund

- PMLiVE

Rethinking immunodermatology: Patient and market insights from leading KOLs and life science leaders

In our new publication, we speak to key opinion leaders and industry experts to uncover novel strategies for commercializing immunodermatology therapies in a crowded market landscape.

Avalere Health

Long exposure image of motion in a tunnel as a metaphor for acceleration and a fast launch

Accelerating HTA and payer submissions: how digital connectivity is driving faster patient access

Sotiria Papanicolaou, Chief Consulting Officer at PRMA Consulting, a member of Fishawack Health, explains how the combination of digital innovation and expert insight are removing roadblocks and speeding up the...

Avalere Health

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

- PMLiVE

Fishawack Health appoints new CEO, Jonathan Koch

Koch will draw on his exceptional experience leading global, customer-centered organizations of scale to build a sustainable future for Fishawack Health.

Avalere Health

- PMLiVE

Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role

Elizabeth Landon brings exceptional leadership from a career supporting and scaling people-based businesses in the professional services and non-profit sectors.

Avalere Health

CHANGING FACES: UNDERSTANDING THE KEY CUSTOMER CONTACT POINTS WITHIN THE ICS LANDSCAPE

As well as creating new structures, the reforms underway within the NHS will see a considerable movement of people and power across the new Integrated Care Systems. Wilmington Healthcare’s Victoria...

Wilmington Healthcare

- PMLiVE

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

The approval for the Novartis drug by the NHS gatekeeper could save 30,000 lives over 10 years

- PMLiVE

NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

- PMLiVE

NICE approval for Lilly’s Verzenios is “fantastic news for thousands of women”

NICE declares Lilly’s breast cancer drug to be cost-effective, allowing routine use on the NHS

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand

The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...

Impetus Digital

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links